SAI Life Sciences

Activities: Manufacturing Research & Development

Trending Articles

  1. Counteracting counterfeits in the pharmaceutical supply chain Sreedhar Patnala, General Manager at Systech, discusses the comprehensive benefits of embracing traceability
  2. Olon commits to ultra-potent compound manufacturing expansion with new €25m facility The CDMO's integrated small and large-scale lines can produce payloads, linker payloads and ultra-potent APIs for customers across Europe
  3. Neogap Therapeutics and NorthX Biologics team up to scale novel cancer cell therapy CDMO NorthX Biologics will work with Neogap to determine advanced manufacturing protocols for Neogap's personalised cancer cell therapy
  4. New kinase inhibitor shows promise for treatment-resistant malaria The single-dose drug may be more effective than current treatments on the market, and works by disabling Plasmodium's ability to splice RNA
  5. Novo Nordisk acquires license to Ascendis Pharma's TransCon tech for up to $286m Novo Nordisk will use the technology to develop, manufacture and commercialise therapeutics for metabolic and cardiovascular diseases

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

Related Content

Manufacturing

Sai Life Sciences to open discovery biology facility at R&D campus

The company's client base works across a set of therapeutic areas including oncology, CNS, antivirals, and inflammation
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Putting people at the core of meeting ever increasing healthcare expectation

The World Health Organization (WHO) defined health in its broader sense in its 1948 constitution as “a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity”; a substantial fraction of the waste in healthcare expenditure results from not knowing what works for particular patients in specific therapeutic indications
Manufacturing

Sai Life Sciences to exhibit at CPhI Worldwide 2017

SAI Life Sciences is a strategic contract development and manufacturing service provider, with a broad technology platform tailored to accelerate discovery, development and commercial supply of regulatory starting materials (RSM), intermediates and new chemical entities (NCE) of pharma and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Revolutionising the pharma supply chain

Establishing a globally competitive, compliant and efficient supply chain that can be managed by a smaller set of Big Pharma innovators is a key industry challenge
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Greater RSM scrutiny puts new constraints on supplier selection

The recent heightened scrutiny of Regulatory Starting Materials requires that manufacturers employ more sophisticated supplier selection criteria, argue Brian Scanlan, MD, Freedom Bioscience Solutions and Marcel Velterop, Chief Commercial Officer, SAI
Regulatory

SAI lays emphasis on RSM quality to ensure compliant API launches

The company has demonstrated an ability to deliver high quality RSMs conforming to the new ICH Q11 guidelines
Manufacturing

CPhI: SAI to emphasise RSM Quality and its new T3 facility

SAI welcomes visitors to Stand 5J10
Subscribe now